Apyx Medical Raises $9.4M Through Stock Offering

An announcement from Apyx Medical ( (APYX) ) is now available.

On November 18, 2025, Apyx Medical Corporation entered into an underwriting agreement with Lucid Capital Markets to issue and sell 2,762,431 shares of common stock, with an option for an additional 414,365 shares, at an offering price of $3.62 per share. The offering, which closed on November 19, 2025, is expected to generate approximately $9.4 million in gross proceeds, which the company plans to use for working capital, corporate purposes, and potential acquisitions, thereby potentially enhancing its market position and operational capabilities.

The most recent analyst rating on (APYX) stock is a Hold with a $4.50 price target. To see the full list of analyst forecasts on Apyx Medical stock, see the APYX Stock Forecast page.

Spark’s Take on APYX Stock

According to Spark, TipRanks’ AI Analyst, APYX is a Neutral.

Apyx Medical’s stock score is driven by a positive earnings call and strong technical momentum, despite financial challenges and valuation concerns. The successful launch of the AYON Body Contouring System and improved financial health are significant positives, while overbought technical indicators and ongoing losses present risks.

To see Spark’s full report on APYX stock, click here.

More about Apyx Medical

Apyx Medical Corporation is a surgical aesthetics company known for its innovative products such as the Helium Plasma Platform Technology, marketed as Renuvion and the AYON Body Contouring System in the cosmetic surgery market, and J-Plasma in the hospital surgical market. The company focuses on providing unique solutions for controlled heat application in surgeries and has a strong presence in the body contouring segment with its FDA-cleared AYON Body Contouring System.

Average Trading Volume: 107,863

Technical Sentiment Signal: Hold

Current Market Cap: $154.1M

For detailed information about APYX stock, go to TipRanks’ Stock Analysis page.